Cargando…

Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors

Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: AlHarbi, Atika, Alshamrani, Majed, Khan, Mansoor, Alnatsheh, Abdelmajid, Aseeri, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680233/
https://www.ncbi.nlm.nih.gov/pubmed/36412906
http://dx.doi.org/10.3390/medsci10040065
_version_ 1784834367255740416
author AlHarbi, Atika
Alshamrani, Majed
Khan, Mansoor
Alnatsheh, Abdelmajid
Aseeri, Mohammed
author_facet AlHarbi, Atika
Alshamrani, Majed
Khan, Mansoor
Alnatsheh, Abdelmajid
Aseeri, Mohammed
author_sort AlHarbi, Atika
collection PubMed
description Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process.
format Online
Article
Text
id pubmed-9680233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96802332022-11-23 Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors AlHarbi, Atika Alshamrani, Majed Khan, Mansoor Alnatsheh, Abdelmajid Aseeri, Mohammed Med Sci (Basel) Article Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process. MDPI 2022-11-21 /pmc/articles/PMC9680233/ /pubmed/36412906 http://dx.doi.org/10.3390/medsci10040065 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
AlHarbi, Atika
Alshamrani, Majed
Khan, Mansoor
Alnatsheh, Abdelmajid
Aseeri, Mohammed
Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title_full Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title_fullStr Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title_full_unstemmed Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title_short Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
title_sort real-world experience of monitoring practice of endocrinopathies associated with the use of novel targeted therapies among patients with solid tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680233/
https://www.ncbi.nlm.nih.gov/pubmed/36412906
http://dx.doi.org/10.3390/medsci10040065
work_keys_str_mv AT alharbiatika realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors
AT alshamranimajed realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors
AT khanmansoor realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors
AT alnatshehabdelmajid realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors
AT aseerimohammed realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors